Table 1 Clinical characteristics in the training and validation cohorts
From: Novel cuproptosis-related long non-coding RNA signature to predict prognosis in prostate carcinoma
Variable | All cohorts (N = 489) | Training cohorts (N = 244) | Validation cohorts (N = 245) | P-value |
|---|---|---|---|---|
Age: n (%) | 0.276 | |||
 < 61 | 221 (45.2%) | 104 (42.6%) | 117 (47.8%) | |
 ≥ 61 | 268 (54.8%) | 140 (57.4%) | 128 (52.2%) | |
Race: n (%) | 0.589 | |||
 American indian or Alaska native | 1 (0.2%) | 1 (0.4%) | - | |
 Asian | 12 (2.5%) | 4 (1.6%) | 8 (3.3%) | |
 Black or african american | 57 (11.7%) | 29 (11.9%) | 28 (11.4%) | |
 White | 406 (83.0%) | 202 (82.8%) | 204 (83.3%) | |
 Not reported | 13 (2.7%) | 8 (3.3%) | 5 (2.0%) | |
M stage: n (%) | 0.558 | |||
 M0 | 447 (91.4%) | 223 (91.4%) | 224 (91.4%) | |
 M1 | 2 (0.4%) | 2 (0.8%) | - | |
 Mx | 40 (8.2%) | 19 (7.8%) | 21 (8.6%) | |
N stage: n (%) | 0.841 | |||
 N0 | 340 (69.5%) | 169 (69.3%) | 171 (69.8%) | |
 N1 | 79 (16.2%) | 38 (15.6%) | 41 (16.7%) | |
 Nx | 70 (14.3%) | 37 (15.2%) | 33 (13.5%) | |
T stage: n (%) | 0.916 | |||
 T2 | 187 (38.2%) | 95 (38.9%) | 92 (37.6%) | |
 T3 | 291 (59.5%) | 144 (59.0%) | 147 (60.0%) | |
 T4 | 11 (2.2%) | 5 (2.0%) | 6 (2.4%) | |
Gleason score: n (%) | 0.762 | |||
 6 | 45 (9.2%) | 26 (10.7%) | 19 (7.8%) | |
 7 | 243 (49.7%) | 120 (49.2%) | 123 (50.2%) | |
 8 | 63 (12.9%) | 32 (13.1%) | 31 (12.7%) | |
 9 | 135 (27.6%) | 64 (26.2%) | 71 (29.0%) | |
 10 | 3 (0.6%) | 2 (0.8%) | 1 (0.4%) | |